Expert view on Creo's tech

In a well-attended Capital Markets Day on Nov 7, Creo made no new announcements but showed qualitatively how the next few years are likely to evolve with insights from three enthusiastic medical users. We took on board three important qualitative observations from the event.Firstly, the importance

MARWYN VALUE INVESTORS LIMITED - Factsheet 30 September 2023

Driving forward R&D programmes while seeking partners

Poolbeg Pharma continues to advance its lead programmes and has struck a collaboration that may lead to its first out-licensing deal. The company is also continuing its campaign to find a partner and effectively monetise its phase II-ready lead compound POLB 001, which they are expanding into oncol

Sonoro Gold files its preliminary economic assessment

Sonoro Gold has now filed its preliminary economic assessment (PEA) on SEDAR for the production of 33,000 ounces of gold equivalent over a nine-year life of mine at the Cerro Caliche Gold Project, located in Sonoro State, Mexico (Figure 1).Compared to previous versions of the PEA, completed in 2021

Sirius Real Estate: Steadfast growth amidst economic headwinds

Sirius Real Estate, the premier owner and operator of branded business and industrial parks in Germany and the UK, brings to light two salient announcements since our last communication on June 13. The company demonstrates resilience and operational coherence with a 7.7% rise in like-for-like rent

Pantheon International PLC - Factsheet August 2023

Shield Therapeutics: Accrufer progressing nicely, new finance put in p...

Shield Therapeutics' Q2 results and commentary suggest the US commercialisation of Accrufer (ferric maltol), which is conducted in collaboration with Viatris, continues to go well. However, the company has trimmed back its prescription volume guidance by c15-20% and highlighted that a high level of

Voyageur Pharmaceuticals advances barium product pipeline

Voyageur Pharmaceuticals has announced the successful formulation and engineering for production of HDXBa, another barium contrast product in the company's pipeline. Voyageur has a bold strategy to use its expertise in natural resources to create an integrated value chain in radiology contrast agen

Expansion to sustain growth with boosted capacity

hVIVO is establishing a new facility in the Canary Wharf life sciences hub, London. This will increase its quarantine bed capacity and provide greater flexibility to meet anticipated higher demand for its human challenge clinical trial services. The new site, which management notes is mostly funded

Sonoro Gold's Robust PEA

Sonoro Gold has announced the results of the new Preliminary Economic Assessment (PEA) of the Cerro Caliche Gold Project, located in Sonoro State, Mexico.The PEA returned a post-tax net present value (NPV) of US$47.7 million and a post-tax internal rate of return (IRR) of 45% for an open pit oxide

Phase Ia progressing successfully; new COVID strain

The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the development of Nanoviricides' (NV) novel and innovative anti-virus therapy, NV-CoV-2 uses a sophisticated polymer (NV-387) as the active ingredient to trap and disrupt viruses in the blood. The therapy aims to reduce the viral l

Marwyn Investment Management Factsheet June 2023

Shield Therapeutics : First signs of hoped-for Accrufer Rx inflection

Shield Therapeutics' recent Q2 trading update showed some early signs of the hoped for upward inflection in the US Accrufer (ferrric maltol) trajectory, as the joint marketing operation with Viatris became operational over the period. Key performance indicators reported included US prescription vol

Tiziana Moving forward in MS and AD

Tiziana is close to being able to start the important phase IIa study with its lead product, intranasal foralumab, in non-active secondary progressive multiple sclerosis (SPMS) and is well advanced in its plan to initiate a separate study in Alzheimer's disease (AD).Within the next two months, Tizi

OCT enters clinical development with 201

Oxford Cannabinoid Technologies (OCT) develops a range of cannabinoid-derived pharmaceuticals. The key news is that the Phase 1 dose and safety study of its lead indication OCT461201 (“201”) with up to 32 volunteers has started.The phase I should be followed by a phase II in patients with establish

Pantheon International Factsheet May 2023

COVID-19 therapy trial underway, RSV trial to follow

Nanoviricides (NV) has announced its first clinical study, a key milestone in the development of its novel and innovative anti-virus therapy, NV-CoV-2. The technology uses a sophisticated large polymer (NV-387) to trap and disrupt viruses in the blood. The therapy aims to reduce the viral load to p

Sonoro Gold Corp: New PEA and gold production draw nearer

Sonoro Gold Corp. has successfully defined a significant oxide gold deposit at shallow depths at the Cerro Caliche Project, Mexico. Cerro Caliche has a NI 43-101 compliant total mineral resources estimate of 440,000 ounces of gold equivalent at an average grade of 0.45 grams per tonne (g/t) gold eq

Upper GI opportunities opened up

Creo Medical announced in June important upper gastrointestinal (GI) procedures EU clearance for its flagship product Speedboat Inject — its dual-energy endoscopy tool which uses radiofrequency and microwave energy for integrated cutting and coagulation functionality. Before, Speedboat was only cle

Alpha FMC: Record Growth and a Bright Medium-Term Outlook

Alpha Financial Markets Consulting plc (Alpha FMC) recently published its full-year audited results for the fiscal year ended 31 March 2023 (FY23). Alpha FMC is a leading global provider of specialist consultancy services to the asset management, wealth management, and insurance industries. The yea